PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23555843-4	2013	Additionally, EFV was found to activate glycogen synthase kinase 3 beta (GSK3beta) in platelets, and we now show that valproic acid (VPA), a known GSK3beta inhibitor, was able to attenuate the release of sCD40L in HIV infected individuals receiving EFV, and in isolated human platelets.	efavirenz	14-17	glycogen synthase kinase 3 beta	Homo sapiens	40-71	
23555843-4	2013	Additionally, EFV was found to activate glycogen synthase kinase 3 beta (GSK3beta) in platelets, and we now show that valproic acid (VPA), a known GSK3beta inhibitor, was able to attenuate the release of sCD40L in HIV infected individuals receiving EFV, and in isolated human platelets.	efavirenz	14-17	glycogen synthase kinase 3 beta	Homo sapiens	73-81	
23555843-4	2013	Additionally, EFV was found to activate glycogen synthase kinase 3 beta (GSK3beta) in platelets, and we now show that valproic acid (VPA), a known GSK3beta inhibitor, was able to attenuate the release of sCD40L in HIV infected individuals receiving EFV, and in isolated human platelets.	efavirenz	14-17	glycogen synthase kinase 3 beta	Homo sapiens	147-155	
23555843-4	2013	Additionally, EFV was found to activate glycogen synthase kinase 3 beta (GSK3beta) in platelets, and we now show that valproic acid (VPA), a known GSK3beta inhibitor, was able to attenuate the release of sCD40L in HIV infected individuals receiving EFV, and in isolated human platelets.	efavirenz	249-252	glycogen synthase kinase 3 beta	Homo sapiens	73-81